Literature DB >> 10727629

Melatonin reversal of DOI-induced hypophagia in rats; possible mechanism by suppressing 5-HT(2A) receptor-mediated activation of HPA axis.

V Raghavendra1, S K Kulkarni.   

Abstract

Serotonin type 2A (5-HT(2A)) receptor-mediated neurotransmitter is known to activate hypothalamic-pituitary-adrenal (HPA) axis, regulate sleep-awake cycle, induce anorexia and hyperthermia. Interaction between melatonin and 5-HT(2A) receptors in the regulation of the sleep-awake cycle and head-twitch response in rat have been reported. Previous studies have shown that melatonin has suppressant effect on HPA axis activation, decreases core body temperature and induces hyperphagia in animals. However, melatonin interaction with 5-HT(2A) receptors in mediation of these actions is not yet reported. We have studied the acute effect of melatonin and its antagonist, luzindole on centrally administered (+/-)-1-(2, 5-dimethoxy-4-iodophenyl) 2-amino propane (DOI; a 5-HT(2A/2C) agonist)-induced activation of HPA axis, hypophagia and hyperthermia in 24-h food-deprived rats. Like ritanserin [(1 mg/kg, i.p.) 5-HT(2A/2C) antagonist], peripherally administered melatonin (1.5 and 3 mg/kg, i.p.) did not affect the food intake, rectal temperature or basal adrenal ascorbic acid level. However, pretreatment of rats with it significantly reversed DOI (10 microgram, intraventricular)-induced anorexia and activation of HPA axis. But the hyperthermia induced by DOI was not sensitive to reversal by melatonin. Mel(1) receptor subtype antagonist luzindole (5 microgram, intraventricular) did not modulate the DOI effect but antagonized the melatonin (3 mg/kg, i.p.) reversal of 5-HT(2A) agonist response. The present data suggest that melatonin reversal of DOI-induced hypophagia could be due to suppression of 5-HT(2A) mediated activation of HPA axis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10727629     DOI: 10.1016/s0006-8993(00)02031-x

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  7 in total

1.  Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial.

Authors:  Egidio Del Fabbro; Rony Dev; David Hui; Lynn Palmer; Eduardo Bruera
Journal:  J Clin Oncol       Date:  2013-02-25       Impact factor: 44.544

2.  Acetyl-L-Carnitine via Upegulating Dopamine D1 Receptor and Attenuating Microglial Activation Prevents Neuronal Loss and Improves Memory Functions in Parkinsonian Rats.

Authors:  Sonu Singh; Akanksha Mishra; Neha Srivastava; Rakesh Shukla; Shubha Shukla
Journal:  Mol Neurobiol       Date:  2016-12-14       Impact factor: 5.590

3.  Exogenous daytime melatonin modulates response of adolescent mice in a repeated unpredictable stress paradigm.

Authors:  Adejoke Yetunde Onaolapo; Ajibola Nurudeen Adebayo; Olakunle James Onaolapo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-11-14       Impact factor: 3.000

4.  Altered sleep architecture and higher incidence of subsyndromal depression in low endogenous melatonin secretors.

Authors:  Shadab Ataur Rahman; Shai Marcu; Leonid Kayumov; Colin Michael Shapiro
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-12-18       Impact factor: 5.270

5.  ALCAR Exerts Neuroprotective and Pro-Neurogenic Effects by Inhibition of Glial Activation and Oxidative Stress via Activation of the Wnt/β-Catenin Signaling in Parkinsonian Rats.

Authors:  Sonu Singh; Akanksha Mishra; Shubha Shukla
Journal:  Mol Neurobiol       Date:  2015-07-30       Impact factor: 5.590

Review 6.  Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics.

Authors:  Emmanuelle A D Schindler; Ryan M Wallace; Jordan A Sloshower; Deepak C D'Souza
Journal:  Front Pharmacol       Date:  2018-03-01       Impact factor: 5.810

7.  The effects of six-day SSRI administration on diurnal cortisol secretion in healthy volunteers.

Authors:  Amy Ronaldson; Livia A Carvalho; Karen Kostich; Antonio Ivan Lazzarino; Livia Urbanova; Andrew Steptoe
Journal:  Psychopharmacology (Berl)       Date:  2018-10-03       Impact factor: 4.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.